WO2016080666A2 - Composition permettant de prévenir ou de traiter les caries dentaires et une parodontopathie, contenant de l'extrait d'ambrosia trifida l. ou une fraction de celle-ci comme principe actif - Google Patents

Composition permettant de prévenir ou de traiter les caries dentaires et une parodontopathie, contenant de l'extrait d'ambrosia trifida l. ou une fraction de celle-ci comme principe actif Download PDF

Info

Publication number
WO2016080666A2
WO2016080666A2 PCT/KR2015/011243 KR2015011243W WO2016080666A2 WO 2016080666 A2 WO2016080666 A2 WO 2016080666A2 KR 2015011243 W KR2015011243 W KR 2015011243W WO 2016080666 A2 WO2016080666 A2 WO 2016080666A2
Authority
WO
WIPO (PCT)
Prior art keywords
extract
maple leaf
fractions
active ingredient
fraction
Prior art date
Application number
PCT/KR2015/011243
Other languages
English (en)
Korean (ko)
Other versions
WO2016080666A3 (fr
Inventor
김은실
오경희
백광현
Original Assignee
대한민국(환경부 국립생물자원관장)
영남대학교산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 대한민국(환경부 국립생물자원관장), 영남대학교산학협력단 filed Critical 대한민국(환경부 국립생물자원관장)
Publication of WO2016080666A2 publication Critical patent/WO2016080666A2/fr
Publication of WO2016080666A3 publication Critical patent/WO2016080666A3/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea

Definitions

  • the present invention relates to a composition for preventing or treating tooth decay and periodontal disease containing maple leaf ragweed extract or fractions thereof as an active ingredient, and more specifically, cavities or periodontitis bacterium containing maple leaf ragweed extract or fractions thereof as an active ingredient.
  • Tooth decay means that the tooth eats insects and the hard tissue of the tooth is eroded and is a symptom of deficiency, also known as caries. Tooth decay is an infectious bacterial disease that causes pain that dissolves and destroys some of the hard calcified tissue of the tooth and eventually loses it, the most common periodontal disease.
  • Periodontitis is an inflammation of the supporting tissues surrounding the teeth and is a chronic inflammatory disease caused by bacteria and toxins in the microbial plaque, and the periodontal tissue supporting the teeth is gradually destroyed, which causes the teeth to shake and finally fall out.
  • Periodontitis is an idiom and is often referred to as flavor, and it is also called periodontal disease or periodontal disease. When periodontitis occurs, the gums settle down and the roots of the teeth appear, causing the symptom.
  • Various oral diseases including dental caries, gingivitis and periodontitis, can be caused by a variety of causes.
  • the causes can be broadly divided into systemic causes and local causes, more important of which are known to be local causes.
  • the most important local cause is bacteria that reside in the oral cavity, ie pathogenic microorganisms.
  • the pathogenic microorganisms resident in the oral cavity attach to the tooth surface, and after a few hours, they form a bacterial community called plaque and multiply, and initially the pathogenic microorganisms adhere to the surface of the upper teeth.
  • plaque By forming plaque, but gradually progressing, plaque is also formed on the tooth surface under the gingiva.
  • the pathogenic microorganisms produce an acid by using sugars in the oral cavity, and the acid can cause tooth decay by demineralizing the mineral that is the main component of the tooth.
  • Microorganisms that play the most important role in inducing oral diseases as described above include Streptococcus mutans and Porphyromonas gingivalis .
  • Streptococcus mutans is a causative agent of caries, and causes various oral diseases.
  • antimicrobial agents including antibiotics having bactericidal and bacteriostatic effects on the microorganisms have been developed as inhibitors and treatments for tooth decay, periodontal disease or gingivitis.
  • Conventionally used materials include compounds containing fluorine and chlorine, such as sodium copper chlorophyllin, sodium fluoride or benzethonium chloride, benzoic aicd, and the like.
  • Korean Patent No. 1280868 discloses a pharmaceutical composition and food composition for preventing or treating dental caries and periodontal disease containing yacon extract as an active ingredient
  • Korean Patent Publication No. 2011-0103267 discloses 'gold leaf extract' Oral composition for the prevention and treatment of tooth decay or periodontitis as an active ingredient 'is disclosed, but there is no description about the composition for caries and periodontal disease prevention or treatment containing the maple leaf extract or fractions thereof of the present invention as an active ingredient. .
  • the present invention was derived by the above-mentioned demands, and the present inventors confirmed that the methanol extract and its fractions of the maple leaf ragweed showed antimicrobial activity against Streptococcus mutans and the periodontal bacterium Porphyromonas gingivalis The present invention has been completed.
  • the present invention provides an antimicrobial composition against cavities or periodontitis bacteria containing maple leaf ragweed extract or fractions thereof as an active ingredient.
  • the present invention provides a pharmaceutical composition for the prevention or treatment of caries or periodontal disease containing maple leaf botanical extract or fractions thereof as an active ingredient.
  • the present invention provides a health functional food composition for the prevention or improvement of tooth decay or periodontal disease containing maple leaf botanical extract or fractions thereof as an active ingredient.
  • the composition containing the extract of the maple leaf ragweed extract or the extract of the maple leaf ragweed extract according to the present invention shows excellent antimicrobial activity against Streptococcus mutans bacteria and periodontitis Porphyromonas gingivalis bacteria It can be used as a pharmaceutical composition for caries and periodontal disease prevention or treatment such as disease prevention, removal of tartar and sterilization of caries, and health functional food composition for preventing or improving caries and periodontal disease.
  • maple leaf pigweed extract or fractions thereof of the present invention is to utilize the discarded plants, it is possible to increase the utilization of plant resources.
  • MeOH ex methanol extract
  • BuOH fr butanol fraction of methanol extract
  • CHCl 3 fr chloroform fraction of methanol extract
  • EtOAc fr ethyl acetate fraction of methanol extract
  • Hexane fr hexane fraction of methanol extract.
  • Figure 2 is a result showing the growth inhibition rate for Porphyromonas gingivalis bacteria of methanol extract and its fractions of maple leaf ragweed.
  • MeOH ex methanol extract
  • BuOH fr butanol fraction of methanol extract
  • CHCl 3 fr chloroform fraction of methanol extract
  • EtOAc fr ethyl acetate fraction of methanol extract
  • Hexane fr hexane fraction of methanol extract.
  • the present invention provides an antimicrobial composition against cavities or periodontitis bacteria containing maple leaf ragweed extract or fractions thereof as an active ingredient.
  • the caries may be Streptococcus mutans , Streptococcus sobrinus , Lactobacillus salivarius , etc.
  • Streptococcus mutans ( Streptococcus mutans ) may be, but not limited to, the periodontal bacterium is Porphyromonas gingivalis , Tannerella forsythia , Fusobacterium nucleotum nucleatum ) and Actinobacillus actinomycetemcomitans , and the like, and preferably Porphyromonas gingivalis , but is not limited thereto.
  • the maple leaf pigweed extract may be an extract such as a leaf, stem or inflorescence which is the ground portion of the plant, and preferably may be an extract using a leaf or inflorescence region, It is not limited.
  • the maple leaf ragweed extract may be water, methanol, ethanol, propanol, butanol or a mixed solvent extract of dried maple leaf ragweed, preferably the methanol extract of dried maple leaf ragweed, specifically After using dried soybeans, dried 2 ⁇ 3cm of maple leaf, dried at 2 ⁇ 4 days at a temperature of 30 ⁇ 50 °C, 75 ⁇ 85% of methanol is added to 400 ⁇ 600g dry weight, and extracted using an ultrasonic device. It may be prepared by.
  • the fraction of the maple leaf ragweed extract is mixed with 400 to 600 g of dried maple leaf ragweed, 75-85% methanol, extracted using an ultrasonic device, filtered and then vacuumed. Methanol extract from which the solvent is removed in the state is dissolved in water, and then obtained by adding chloroform or hexane (n-hexane).
  • the present invention also provides a pharmaceutical composition for the prevention or treatment of caries or periodontal disease, containing the maple leaf ragweed extract or a fraction thereof as an active ingredient.
  • Periodontitis gingivitis and periodontitis depending on the severity of the disease. It is a relatively light and fast-recovering form of periodontal disease that is limited to the gums, ie soft tissues, is called gingivitis, and when this inflammation progresses to the gums and around the gum bone, it is called periodontitis.
  • Extracts or fractions of the invention may comprise suitable carriers, excipients and diluents conventionally used in the manufacture of pharmaceutical compositions.
  • compositions or fractions of the present invention may be used in the form of their pharmaceutically acceptable salts, and may be used alone or in combination with other pharmaceutically active compounds as well as in a suitable collection.
  • the extracts or fractions according to the invention are each formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, oral formulations, external preparations, suppositories, and sterile injectable solutions according to conventional methods. Can be used.
  • Carriers, excipients and diluents that may be included in the extract or fraction include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose And various compounds or mixtures including methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil and the like.
  • Solid preparations for oral administration include tablets, pills, powders, granules, capsules and the like, and such solid preparations may contain at least one excipient such as starch, calcium carbonate and sucrose in the extract or fraction. (sucrose), lactose (lactose), gelatin, etc. are mixed and prepared. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used.
  • Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin.
  • Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories.
  • the non-aqueous solvent and suspending agent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used.
  • As the base of the suppository witepsol, macrogol, tween 60, cacao butter, laurin butter, glycerogelatin and the like can be used.
  • Preferred dosages of the extracts or fractions of the present invention vary depending on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the duration, and may be appropriately selected by those skilled in the art.
  • the extract or fraction of the present invention is preferably administered at 0.0001 to 100 mg / kg, preferably at 0.001 to 100 mg / kg. Administration may be administered once a day or may be divided several times. The dosage does not limit the scope of the invention in any aspect.
  • Extracts or fractions of the invention can be administered to a variety of routes to mammals, such as mice, mice, livestock, humans. All modes of administration can be expected, for example oral, by injection.
  • the present invention provides a health functional food composition for the prevention or improvement of tooth decay or periodontal disease containing maple leaf botanical extract or fractions thereof as an active ingredient.
  • the extract of the maple leaf ragweed or the fractions thereof of the present invention shows excellent antimicrobial activity against the cavities Streptococcus mutans and periodontitis Porphyromonas gingivalis, so it is useful for the prevention or improvement of periodontal diseases such as caries or gingivitis. Can be used.
  • the extract or fraction of the present invention When the extract or fraction of the present invention is used as a food additive, the extract or fraction may be added as it is or used with other food or food ingredients, and may be appropriately used according to a conventional method.
  • the mixed amount of the active ingredient can be suitably determined according to the purpose of use (prevention, health or therapeutic treatment).
  • the extracts or fractions of the invention are added in an amount of up to 15 parts by weight, preferably up to 10 parts by weight relative to the raw materials.
  • the amount may be below the above range, and the active ingredient may be used in an amount above the above range because there is no problem in terms of safety. .
  • the kind of food there is no particular limitation on the kind of food.
  • the food to which the extract or fraction may be added include meat, sausage, bread, chocolate, candy, snacks, confectionary, pizza, ramen, other noodles, gums, dairy products including ice cream, various soups, drinks, teas, Drinks, alcoholic beverages and vitamin complexes, and the like includes all of the dietary supplements in the conventional sense.
  • Extracts of Ambrosia trifida were used above the ground of maple leaf, using leaves, stems and inflorescences.
  • the leaves and inflorescences of the maple leaf identified by the plant taxonomy, were cut evenly to 2.54 cm using small green beans, and dried in a drying oven at 40 ° C. for 3 days.
  • a plant dry weight of about 500 g the resultant was extracted with an ultrasonic device in 80% methanol, and these liquids were filtered through a membrane filter (0.2 ⁇ m), and then the solvent was removed under vacuum to leave a methanol extract.
  • the maple leaf vinegar extract is a methanol extract mainly containing a trace component of the maple leaf ragweed. All solvents used were analytical grade, purchased from Sigma-Aldrich (USA) or Merck (USA).
  • the fractions of the maple leaf ragweed extract were dissolved in the methanol leaf ragweed methanol extract, and then fractionated using butanol, chloroform (CHCl 3 ), ethyl acetate or hexane (n-hexane).
  • the fractionated sample was passed through a membrane filter (0.2 ⁇ m) before freeze drying and the solvent was removed in vacuo leaving only each fraction. These fractions were stored until use in a -20 ° C. freezer. All solvents used were analytical grade, purchased from Sigma-Aldrich (USA) or Merck (USA).
  • maple leaf ragweed extract or fractions thereof may be used for the prevention or treatment of caries or periodontal disease.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Botany (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Veterinary Medicine (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne : une composition antimicrobienne pour Streptococcus mutans ou bactéries parodontales, contenant un extrait d'Ambrosia trifida L. ou des fractions de celle-ci en tant que principe actif ; une composition pharmaceutique permettant de prévenir ou de traiter des caries dentaires ou une parodontopathie, contenant un extrait d'Ambrosia trifida L. ou des fractions de celle-ci en tant que principe actif ; et une composition d'aliment fonctionnel de santé permettant de prévenir ou d'améliorer des caries dentaires ou une parodontopathie, contenant un extrait d'Ambrosia trifida L. ou des fractions de celle-ci en tant que principe actif.
PCT/KR2015/011243 2014-11-19 2015-10-23 Composition permettant de prévenir ou de traiter les caries dentaires et une parodontopathie, contenant de l'extrait d'ambrosia trifida l. ou une fraction de celle-ci comme principe actif WO2016080666A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020140161278A KR101625412B1 (ko) 2014-11-19 2014-11-19 단풍잎돼지풀 추출물 또는 이의 분획물을 유효성분으로 함유하는 충치와 치주질환 예방 또는 치료용 조성물
KR10-2014-0161278 2014-11-19

Publications (2)

Publication Number Publication Date
WO2016080666A2 true WO2016080666A2 (fr) 2016-05-26
WO2016080666A3 WO2016080666A3 (fr) 2016-07-14

Family

ID=56014653

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2015/011243 WO2016080666A2 (fr) 2014-11-19 2015-10-23 Composition permettant de prévenir ou de traiter les caries dentaires et une parodontopathie, contenant de l'extrait d'ambrosia trifida l. ou une fraction de celle-ci comme principe actif

Country Status (2)

Country Link
KR (1) KR101625412B1 (fr)
WO (1) WO2016080666A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220160325A (ko) * 2021-05-27 2022-12-06 (주)아로마뉴텍 단풍잎돼지풀 초임계 추출물 및 이의 용도

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011137420A1 (fr) * 2010-04-30 2011-11-03 Apellis Pharmaceuticals, Inc. Procédés, articles et trousses pour la désensibilisation allergique par l'intermédiaire des muqueuses orales

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220160325A (ko) * 2021-05-27 2022-12-06 (주)아로마뉴텍 단풍잎돼지풀 초임계 추출물 및 이의 용도
KR102534818B1 (ko) 2021-05-27 2023-05-26 (주)아로마뉴텍 단풍잎돼지풀 초임계 추출물 및 이의 용도

Also Published As

Publication number Publication date
KR101625412B1 (ko) 2016-05-31
KR20160059603A (ko) 2016-05-27
WO2016080666A3 (fr) 2016-07-14

Similar Documents

Publication Publication Date Title
KR101775613B1 (ko) 망고스틴 추출물 또는 알파, 감마 망고스틴을 유효성분으로 포함하는 치주질환 예방 또는 개선용 조성물
WO2018062605A1 (fr) Composition de dentifrice contenant un extrait galénique
KR20190000955A (ko) 혼합 추출물을 함유하는 치주질환 예방 또는 치료용 조성물
WO2005091937A2 (fr) Compositions utilisees dans le traitement d'infections microbiennes
KR100967040B1 (ko) 항치주병균 조성물, 상기 항치주병균 조성물을 함유하는항치주병용 음식물 및 구강용 세정제
KR102217525B1 (ko) 치주염 예방 또는 치료용 유산균 및 그의 용도
KR101951024B1 (ko) D-갈락토오스를 포함하는 쿼럼센싱 저해제
WO2016080666A2 (fr) Composition permettant de prévenir ou de traiter les caries dentaires et une parodontopathie, contenant de l'extrait d'ambrosia trifida l. ou une fraction de celle-ci comme principe actif
KR20140031512A (ko) 오미자 추출물을 포함하는 구강질환 치료 및 구취 억제용 조성물
US20050152852A1 (en) Use of antibacterial component extracted from cacao mass for inhibiting the growth of periodontal bacteria
WO2016182158A1 (fr) Composition contenant de l'extrait de lactuca scariola comme principe actif pour la prévention ou le traitement de la maladie parodontale
KR101634210B1 (ko) 캠페롤을 유효성분으로 함유하는 충치와 치주질환 예방 또는 치료용 조성물
WO2016182147A1 (fr) Composition contenant de l'extrait de solanum carolinense comme principe actif pour la prévention ou le traitement de la maladie parodontale
KR101671061B1 (ko) 발효 지실 추출물을 유효성분으로 포함하는 치주 질환 예방 또는 치료용 조성물
KR101280868B1 (ko) 야콘 추출물을 유효성분으로 함유하는 충치와 치주질환 예방 또는 치료용 약학조성물 및 식품 조성물
KR101685671B1 (ko) 네로올리돌을 포함하는 강진향 추출물을 포함하는 치주질환 예방 또는 치료용 약학 조성물
KR101627528B1 (ko) 미국자리공 추출물 또는 이의 분획물을 유효성분으로 함유하는 충치와 치주질환 예방 또는 치료용 조성물
KR20160059606A (ko) 아까시나무 추출물 또는 이의 분획물을 유효성분으로 함유하는 충치와 치주질환 예방 또는 치료용 조성물
KR102217518B1 (ko) 치주염 예방 또는 치료용 유산균 및 그의 용도
WO2016182157A1 (fr) Composition contenant de l'extrait de tragopogon dubius comme principe actif pour la prévention ou le traitement de la maladie parodontale
KR20130131973A (ko) 오리나무 수피 추출물 및 유산균을 포함하는 항우식성 조성물
KR101555214B1 (ko) 소포라플라바논 g 및 홍삼 농축액의 혼합물을 유효성분으로 함유하는 치아우식증 및 치주질환을 예방, 개선 또는 치료하기 위한 조성물
KR20130059741A (ko) 민대극 추출물을 포함하는 관절염 예방 및 치료용 조성물
KR101834758B1 (ko) 봉독을 유효성분으로 포함하는 치주염의 예방 또는 치료용 조성물
WO2011129495A1 (fr) Procédé d'extraction d'une substance anticarie à partir de réglisse

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15860378

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15860378

Country of ref document: EP

Kind code of ref document: A2